People Want an Alzheimer’s Drug. Aducanumab Isn’t the One.

NYT > Top Stories Michael Greicius and G. Caleb AlexanderAn F.D.A. sign-off for aducanumab would make finding a good treatment harder. May 28, 2021 at 10:25PM https://ift.tt/34psXgz